Why Vaxart Stock Plunged 28.5% in December

1 min read

Shares of Vaxart (NASDAQ: VXRT) tumbled 28.5% in December, according to data provided by S&P Global Market Intelligence, as investors continued to take stock of its oral COVID-19 vaccine.

The biotech rocketed to stratospheric heights earlier in the year on the promise that a coronavirus pill would be much better received by the public and the medical community. You wouldn’t need to get a needle (or two), as is required with both Moderna‘s and the PfizerBioNTech vaccines, and being shelf stable, it doesn’t require refrigeration, unlike the competing vaccines, which have a relatively short shelf life.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Up Over 200% in 3 Years, This 5G Stock Isn’t Done Soaring Yet

Next Story

Tesla Is Worth $700 Billion. Here’s How to Find the Next Tesla-Like Stocks

Latest from Blog